Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica

@article{Shimizu2017GlucoseregulatedP7,
  title={Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica},
  author={Fumitaka Shimizu and Kristin L Schaller and Gregory P. Owens and Anne C. Cotleur and Debra Kellner and Yukio Takeshita and Birgit Obermeier and Thomas J. Kryzer and Yasuteru Sano and Takashi Kanda and Vanda A. Lennon and Richard M Ransohoff and Jeffrey L Bennett},
  journal={Science Translational Medicine},
  year={2017},
  volume={9}
}
Neuromyelitis optica (NMO) is an inflammatory disorder mediated by antibodies to aquaporin-4 (AQP4) with prominent blood-brain barrier (BBB) breakdown in the acute phase of the disease. Anti-AQP4 antibodies are produced mainly in the periphery, yet they target the astrocyte perivascular end feet behind the BBB. We reasoned that an endothelial cell–targeted autoantibody might promote BBB transit of AQP4 antibodies and facilitate NMO attacks. Using monoclonal recombinant antibodies (rAbs) from… CONTINUE READING
Highly Cited
This paper has 19 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 48 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 63 references

Clinical utility of testing AQP 4 - IgG in CSF : Guidance for physicians

  • J. P. Fryer Majed, A. McKeon, V. A. Lennon, S. J. Pittock
  • Neurol . Neuroimmunol . Neuroinflamm .
  • 2016

Guidance for physicians

  • M. Majed, J. P. Fryer, A. McKeon, V. A. Lennon, S. J. Pittock, Clinical utility of testing AQP4-IgG in CSF
  • Neurol. Neuroimmunol. Neuroinflamm. 3, e231
  • 2016

Similar Papers

Loading similar papers…